Case Studies
Prolific – Since 1984, we have contributed to the creation of over 100 spin-out companies and continue to hold shares in more than 50 of them.
Diverse – Our portfolio mirrors the breadth of Queen’s research, spanning industries such as software, physics, engineering, pharmacy, and life sciences.
Sustainable – We have supported companies through various paths to success, including organic growth, venture capital, and angel investment.
Explore some of our success stories.
Kainos has over 1,500 people across 13 offices in Europe and North America.
The Group’s Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday, Inc. (‘Workday’), responsible for implementing Workday’s innovative Software–as–a–Service (SaaS) platform for enterprise and, now, government customers.
Continue Reading
-800x450.png)
Fusion Antibodies is dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry.
Fusion Antibodies is a specialists in pre–clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications.
Established in 2001 as a spin–out from Queen’s University Belfast, Fusion Antibodies' mission is to enable drug discovery companies to develop innovative products in a timely and cost–effective manner for the benefit of the global healthcare industry.
The company has an international, blue–chip client base which includes 8 of the top 10 global pharmaceutical companies by revenue.
Continue Reading